{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:48:04Z","timestamp":1790340484299,"version":"4.1.0"},"reference-count":17,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,10,22]],"date-time":"2009-10-22T00:00:00Z","timestamp":1256169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Muscle and Nerve"],"published-print":{"date-parts":[[2010,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Myasthenia gravis (MG) is an immune\u2010mediated disorder with a variable response to treatment. In this study, patients with refractory MG who were treated with rituximab were identified. A review of patients referred to the Yale Neuromuscular Clinic was performed. Patients with refractory MG who were treated with rituximab were reviewed for response to treatment. Patients who had muscle\u2010specific kinase (MuSK<jats:sup>+<\/jats:sup>) or acetylcholine receptor (AChR<jats:sup>+<\/jats:sup>) antibodies were included. Six patients were identified who met the criteria described. All patients tolerated rituximab without side effects and had a reduced need for immunosuppressants and\/or improvement in clinical function. Patients with refractory MG appeared to respond to rituximab in this small, retrospective study. This result suggests that a larger, prospective trial is indicated. Muscle Nerve, 2009<\/jats:p>","DOI":"10.1002\/mus.21521","type":"journal-article","created":{"date-parts":[[2009,10,22]],"date-time":"2009-10-22T14:04:46Z","timestamp":1256220286000},"page":"375-378","source":"Crossref","is-referenced-by-count":86,"title":["Rituximab in the management of refractory myasthenia gravis"],"prefix":"10.1002","volume":"41","author":[{"given":"Nazlee","family":"Zebardast","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huned S.","family":"Patwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Novella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,10,22]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneuro0810"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000313840.27060.bf"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg175"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20169"},{"key":"e_1_2_6_6_2","first-page":"77","article-title":"Complete remission induced by rituximab in refractory, seronegative, muscle\u2010specific, kinase\u2010positive myasthenia gravis","volume":"78","author":"Baek WS","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20479"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-006-0442-2"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2008.02399.x"},{"key":"e_1_2_6_10_2","first-page":"201","article-title":"Sustained response to rituximab in anti\u2010AChR and anti\u2010MuSK positive myasthenia gravis patients","author":"Illa I","year":"2008","journal-title":"J Neuroimmunol"},{"key":"e_1_2_6_11_2","first-page":"1536","article-title":"Loss of CD20 expression following rituximab\u2010combined chemotherapy in CD20\u2010positive and CyclinD1\u2010positive multiple myeloma","volume":"49","author":"Shiratori S","year":"2008","journal-title":"Rinsho Ketsueki"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21577"},{"key":"e_1_2_6_13_2","unstructured":"RXList.http:\/\/www.rxlist.com\/rituxan\u2010drug.htm#"},{"issue":"1","key":"e_1_2_6_14_2","first-page":"A301","article-title":"Pilot trial of rituximab in myasthenia gravis","volume":"70","author":"Tandan R","year":"2008","journal-title":"Neurology"},{"issue":"1","key":"e_1_2_6_15_2","first-page":"A301","article-title":"Rituximab in refractory myasthenia gravis: a follow\u2010up study of patients with anti\u2010AChR or anti\u2010MuSK antibodies","volume":"70","author":"Illa I","year":"2008","journal-title":"Neurology"},{"key":"e_1_2_6_16_2","unstructured":"FDA public health advisory. Life\u2010threatening brain infection in patients with systemic lupus erythematosus after Rituxan (rituximab) treatment.http:\/\/www.fda.gov\/Cder\/Drug\/advisory\/rituximab.htm Dec 18 2008."},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.nrl.0000250948.04681.96"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07718.x"}],"container-title":["Muscle &amp; Nerve"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmus.21521","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.21521","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T23:37:19Z","timestamp":1696894639000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mus.21521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,22]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["10.1002\/mus.21521"],"URL":"https:\/\/doi.org\/10.1002\/mus.21521","archive":["Portico"],"relation":{},"ISSN":["0148-639X","1097-4598"],"issn-type":[{"value":"0148-639X","type":"print"},{"value":"1097-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,22]]}}}